Five-year OS rate was approximately 20% with pembrolizumab plus pemetrexed-platinum in the ITT population (v 11% with placebo plus pemetrexed-platinum) and was higher in patients with higher PD-L1 ...

Pemetrexed (Alimta, Eli Lilly and Company) is a multi‑targeted anticancer antifolate agent that disrupts crucial folate‑dependent metabolic processes essential for cell replication. The most common ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with ...

Background: In a phase III study of P+Cis versus Cis, MPM pts demonstrated a significant survival benefit (12.1 mo vs 9.3 mo median survival; 50.3% vs 38.0% 1-yr survival) and clinical benefit in ...

Fresenius Kabi PEMEtrexed for Injection, USP is an affordable treatment option for adult patients with non-squamous non-small cell lung cancer and malignant pleural mesothelioma.

Interim results from the FLAURA2 study showed that investigator-assessed median progression-free survival (PFS) improved by 8.8 months with osimertinib plus pemetrexed and platinum chemotherapy ...

Pembrolizumab's new MPM approval was based on the KEYNOTE-483 trial, which randomized 440 patients to receive either pembrolizumab for ≤ 2 years in combination with pemetrexed and platinum-based ...

The Food and Drug Administration (FDA) has approved Pemrydi RTU ® (pemetrexed injection), a ready-to-use (RTU) presentation of pemetrexed. The application was approved through the FDA’s 505 (b ...

The acquisition cost of pemetrexed is £800 for a 500-mg vial (excluding VAT, BNF 57th edition). The cost per patient, assuming an average of 8 cycles and a body surface area of 1.79 m 2, is ...